MedTrace Logo

Prediction of Transfusion-Associated Complications

NCT05466370 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3366

Last updated 2023-04-26

No results posted yet for this study

Summary

Currently, about 350000 red blood cell concentrates are produced from blood donations in Austria every year.

In addition to the main effect of replacing lost blood, red blood cell concentrates also have many undesirable effects - from blood group compatibilities, which are easily avoidable due to care, to storage-related side effects, to mostly intensive care problems as a result of massive transfusions, to system-wide effects such as TRALI, TACO and TRIM.

Before being administered to patients, red blood cell concentrates undergo an extensive quality assurance process in which a large number of parameters are collected. Prior to use on patients, for example, bedside tests and tests for further incompatibilities with a blood sample from the intended patient are performed. With the implementation of Patient Blood Management (PBM) in recent years, the use of red cell concentrates has become more targeted - the number of transfusions is decreasing in most developed countries. However, it is still possible to suffer transfusion-related adverse events (TRAE). Thus, active research activity to reduce these TRAEs continues to be called for.

To date, however, it is not known which patients experience transfusion-related adverse events. Despite the broad measures of hemovigilance and pre-transfusion testing, it is still not possible to predict which individual patient will respond to a transfusion with a typical adverse event such as hypotension, hemolysis, renal failure, or TRALI. It seems understandable that characteristics of the patient as well as characteristics of the administered unit could play a role for this. In particular, it is conceivable that a combination of characteristics of the blood unit and characteristics of the patient could determine a complication in the course of administration. For this reason, it seems attractive to use artificial intelligence and machine learning methods to predict any complications.

Conditions

  • Transfusion-dependent Anemia

Interventions

BIOLOGICAL

Transfusion of Allogeneic Blood

Transfusion of Allogeneic Blood

Sponsors & Collaborators

  • Kepler University Hospital

    lead OTHER

Principal Investigators

  • Thomas Tschoellitsch, MD · Kepler University Hospital and Johannes Kepler University, Linz, Austria

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-15
Primary Completion
2022-07-31
Completion
2022-07-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05466370 on ClinicalTrials.gov